The Rhythm Biosciences Ltd (ASX: RHY) has risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.
The post Why the Rhythm (ASX:RHY) share price again reached a new all-time record today appeared first on The Motley Fool Australia. –
It seems like Rhythm Biosciences Ltd (ASX: RHY) can do no wrong by investors at the moment. Today, the company’s shares have risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.
During early morning trade, the Rhythm share price rose to an intraday high of $1.38. However, some profit taking have led its share to slightly retreat to, at the time of writing, $1.35, up 7.14%.
What’s driving the Rhythm share price to new highs?
The Rhythm share price is breaking new highs as investors are fighting to get a hold of its shares.
In its announcement, Rhythm advised that its global manufacturer, Biotem, has completed initial ColoSTAT prototype test kits. The small-scale production of ColoSTAT devices commenced in December, with delivery fulfilled ahead of schedule later that month.
Having received the first prototype units, Rhythm began testing the performance of ColoSTAT test kits with cancerous and healthy blood samples. The company noted that full testing is underway and will form Study 6, due to be completed by March 2021.
Rhythm noted that early quality assurance and performance test work is consistent with its own prototype test results.
Room for improvement
In addition to the assembly of ColoSTAT, the company stated that it has continued its efforts in advancing the technology behind the test kit. The current version, which is considered far superior than the current market standard faecal test, is undergoing improvements.
Rhythm advised it has allocated extra resources to its algorithm and software development division to enhance the existing technology on offer. As more samples arrive, it will use this to create a larger dataset to assess any performance changes made. New developments will be applied to study 7 and onward.
Rhythm CEO, Mr Glenn Gilbert, hailed the milestone achievement, saying:
The objective of design transfer of the core ColoSTAT technology to our global manufacturer, Biotem, is to demonstrate that they are able to produce, in a commercial setting, the same consistent and high performing ColoSTAT test kit that Rhythm had achieved in lab.
The early view on the performance of the test kits manufactured by Biotem provides further confidence on our underlying technology that will drive the success of ColoSTAT into the future.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- Here’s why the Rhythm (ASX:RHY) share price hit an all-time high today
- Rhythm Biosciences (ASX: RHY) share price soars 1300% in 6 months
- Here’s why the Rhythm Bioscience (ASX:RHY) share price is up 15% to a record high
- Here are 3 ASX small cap shares with exciting product launches in 2021
- Why the Rhythm Biosciences (ASX:RHY) share price jumped over 600% this year
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.